ClinicalTrials.gg
Status unknownNCT04659070Updated Dec 9, 2020

To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia

A Phase 3 interventional study of Experimental : Ezetimibe / Rosuvastatin + Telmisartan and Active comparator1 : Ezetimibe / Rosuvastatin in Primary Hypercholesterolemia and Hypertension, sponsored by Hanlim Pharm. Co., Ltd.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2020-12-09.

Sponsored by Hanlim Pharm. Co., Ltd. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2020), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jul 2020, registered Dec 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
19 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing ezetimibe in Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. Ezetimibe · Hypertension.

Planned enrollment
3rd of 13
156 · median 65
Started
2020
with 2 others
Phase 3
6 of 13
1 open now
Registered
6th of 13
by date
Lead sponsor
1 of 13
Hanlim Pharm. Co., Ltd.

Among the 13 studies testing ezetimibe in Hypertension, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2020, is one of 6 in phase 3, and was the 6th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 13 studies testing ezetimibe in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 19 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing ezetimibe in Hypertension, or all of them as a file.
02

Study summary

This study is a multicenter, Randomized, double-blind, acitve-controlled, Phase 3 Clinical Trial in 8 weeks for screening, twice Investigational product administer, Follow up visit.

Read the detailed description

The purpose of this study is to evaluate the efficacy and safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in patients with essential hypertension and primary hypercholesterolemia.

03

Conditions studied

  • Primary Hypercholesterolemia
  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
19 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult male and female aged 19 to 79 years of age
  2. a patient with congenital hypertension and hypercholesterolemia capable of administering medicines for Clinical trials planned for this clinical trial, with the discontinuation of existing therapeutic drugs according to the section.
  3. A person who meets the following criteria at the time of screening (visit 1)

    • MSSBP \< 180mmHg and MSDBP \< 110mmHg
    • LDL-C ≤ 250 mg/dL and TG \< 400 mg/dL (based on organ clinical laboratory testing)
  4. A person who agrees to through a medically permitted contraception method during a clinical trial period.

    • Possible pregnant female test subjects: intrauterine device (IUD) or IUS (Intrauterine system), intractorine defections, double-blocking method (complex use of blocking methods such as male condoms, female condoms, uterine cervical caps, contraceptive diaphragm, contraceptive sponges)
    • Male test subjects with potential pregnant spouses (including partners): hormonal contraception, intrauterine device (IUD) or IUS (Intrauterine system), intraperitoneal failure, double-blocking (male condom, female condom, uterine cervical cap, contraceptive diaphragm, and contraceptive blocking)
  5. Patients who have agreed in writing to voluntarily participate in this clinical trial

Randomized(Visit 2) criteria

  1. If the blood pressure measured at the time of random assignment is as follows:

    • 140mmHg ≤ MSSBP \< 180mmHg and MSDBP \< 110mmHg However, patients with diabetes or chronic neuropathy: 130mmHg ≤ MSSBP \< 180mmHg (In the case of chronic neuropathy patients, albuinuria or proteinuria history is confirmed until the time of random assignment.)
  2. Therapeutic Lifestyle Change (TLC) after Visit 1 A person whose LDL-C and TG values correspond to the following group-specific criteria (NCEP ATP III guideline) as the basis for organ testing at the time of random assignment.

    • Group1 cardiovascular risk factor : 0\~1, LDL-C(mg/dL) : 160-250, TG(mg/dL) : \< 400
    • Group2 cardiovascular risk factor : 2 ≤, 10 year risk : \< 10% LDL-C(mg/dL) : 160-250 TG(mg/dL) : \< 400 cardiovascular risk factor : 2 ≤, 10% ≤ 10 year risk ≤ 20%, LDL-C(mg/dL) : 130-250 TG(mg/dL) : \< 400
    • Group3 coronary artery disease or equivalent (20% \< 10 year risk), LDL-C(mg/dL) : 100-250 TG(mg/dL) : \< 400
  3. A person who does not have any inappropriate items when re-checking the selection/excluding criteria at the time of random assignment.

(except items that apply only to screening)

Exclusion criteria

Exclusion Criteria:

  1. A person suspected of secondary hypertension or secondary hypertension (aortic stenosis, hyperaldosterone haemorrhage, renal vein stenosis, sacrosanctal hypertension, chrome-friendly cell species, Cushing syndrome, polycystic neuropathy, etc.)
  2. Secondary dyslipidemia patients (neurological syndrome, dysplasia, closed liver disease, Cushing syndrome, etc.)
  3. Standing low blood pressure patient with symptoms
  4. ventricular tachycardia, atrial fibrillation, atrial fibrillation, or other arrhythmia patients that the tester has determined to be clinically meaningful.
  5. Persons with non-post-closing myocardial disease, severe closed coronary artery disease, aortic stenosis, hemodynamically meaningful aortic valve or mitral valve stenosis.
  6. Patients with severe heart failure ( class III: Symptoms due to mild exercise/classIV: Symptoms even when stabilized)
  7. A person who has one or more of the following forces within the last six months based on a screening visit (visit 1):

    • Those who have received ischemic heart disease (unstable angina, myocardial infarction), peripheral vascular disease, percutaneous coronary artery extension or coronary artery bypass treatment, etc.
    • Patients with severe cerebrovascular disorders (brain stroke, cerebral infarction, cerebral hemorrhage, routine ischemia, etc.)
  8. A person with a history of gastrointestinal diseases (such as Crohn's disease, ulcers, etc.) and surgery (except simple appendectomy or hernia surgery) that can affect the absorption, distribution, metabolism, and excretion of drugs.
  9. Patients with gastrointestinal diseases such as active gastritis or duodenal ulcer within one year of screening
  10. A person who has a history of muscle toxicity to fibromyalgia, myopathy, rhabdomyolysis, history of hereditary muscle disease or family history, and past HMGCoA reducing enzyme inhibitor or fibrate-related drugs.
  11. Patients with parathyroidism
  12. Patients with shock
  13. Patients with biliary obstruction or bile congestion
  14. Patients with hereditary vascular edema
  15. Patients with a history of vascular edema during ACE inhibitor or Angiotensin II receptor antagonist treatment.
  16. Patients with chronic inflammatory diseases who need continuous anti-inflammatory treatment
  17. Patients with diseases, connective tissue diseases
  18. Those who have a history of moderate degree or malignant retinopathy (i.e., retinal bleeding, vision impairment, retinal micro aneurysm) within the previous six months based on a screening visit (visit 1)
  19. On the basis of a screening visit (visit 1) a person with , including leukemia and lymphoma, was evaluated as Complete Response (but not recurrent within at least two years from the screening date, or a malignant tumor that occurred within the minimum two years of the screening, is the only basal cell carcinoma or squamous skin cell carcinoma (Square).
  20. Patients who have run out of blood or sodium due to high doses of diuretics, dietary salinity, diarrhea and vomiting.
  21. The following institutional clinical laboratory test results (screening criteria) are available:

    • Patients with active liver disease and severe liver disorder (unknown continuous serum , elevated or serum ALT, person with AST more than three times the normal upper limit)
    • a person whose CPK (creatine phosphokinase) level is more than twice the normal upper limit.
    • Creatine clearance () \< 30mL/min or \< 30ml/min/1.73m2.
    • a person with low potassium haemorrhage (less than 3.5 mmol/L) or high potassium haemorrhage (greater than 5.5 mmol/L)
    • Unregulated diabetics ( > 9.0%)
    • Unregulated thyroid dysfunction with a TSH level of 1.5 times or more than the normal upper limit
  22. In case of the following allergic and hypersensitive history:

    • someone with drug allergy-response anaphylaxis or hepatotoxicity.
    • Angiotensin II receptor blocker family drug or HMG-CoA reducing enzyme inhibitor
    • A person who has overreacted to a clinical trial drug or is hypersensitive to the composition of a clinical trial drug
    • A person who has genetic problems such as galactose intolerance, Lap lactase deficiencies, or glucose-galactose malabsorbtion.
  23. A person who is administering a prohibited drug in this clinical trial or is expected to be administered during the clinical trial period.
  24. Those who showed a difference of SBP ≥ 20 mmHg and DBP ≥10 mmHg in three consecutive measurements at least two minutes apart on each arm during a screening visit (visit 1)
  25. Patients who cannot stop anti-hypertensive drugs or lipid-control drugs that were being administered during a screening visit (visit 1) during the clinical trial period.
  26. Those who have or are suspected of drug or alcohol abuse within one year prior to the screening visit (visit 1)
  27. Pregnant or breastfeeding women
  28. A person who has received another clinical trial medication within three months of the first administration of the clinical trial medication in this clinical trial (if he/she has not administered the clinical trial medication or has participated in non-release observation research, he/she may register).
  29. A person who is deemed unfit by the tester (the physician in charge) to participate in this clinical trial
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    Experimental : Ezetimibe / Rosuvastatin + Telmisartan

    Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks

    Drug: Experimental : Ezetimibe / Rosuvastatin + Telmisartan

  • Active comparator
    Active comparator1 : Ezetimibe / Rosuvastatin

    Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks

    Drug: Active comparator1 : Ezetimibe / Rosuvastatin

  • Active comparator
    Active comparator2 : Telmisartan

    Telmisartan 80mg PO, Once daily for 8 weeks

    Drug: Active comparator2 : Telmisartan

Interventions

06

What researchers measure

Primary outcomes

  1. Mean sitting systolic blood pressure (MSSBP)

    MSSBP change at week 8 compared to baseline, experimental, active comparator1

    Time frame: baseline, week 8

  2. Low density lipoprotein cholesterol (LDL-C)

    LDL-C change at week 8 compare to baseline, experimental, active comparator2

    Time frame: baseline, week 8

Secondary outcomes

  1. Mean sitting systolic blood pressure (MSSBP)

    MSSBP change at week 4 compare to basline, experimental, active comparator1

    Time frame: baseline, week 4

  2. Mean sitting diastolic blood pressure (MSDBP)

    MSDBP change at week 4, 8 compare to baseline, experimental, active comparator1

    Time frame: baseline, week 4, week 8

  3. the rate of patients who have reached their target blood pressure

    The rate of patients who have reached their target blood pressure in experimental and active comparator1 at 4 or 8 weeks after administration of clinical trial medications (Average left blood pressure \< 140/90mmHg, diabetic or chronic renal disease (only for patients with chronic renal disease with albu manure or proteinuria history) Average left and right blood pressure / 130/80mmHg)

    Time frame: week4, week8

  4. Percentage of LDL-C change

    Percentage of LDL-C change at week 4 compare to baseline, experimental, active comparator2

    Time frame: baseline, week4

  5. LDL-C change

    LDL-C change at week 4, 8 compare to baseline, experimental, active comparator2

    Time frame: baseline, week4, week8

  6. Achievement rate of LDL-C treatment goals

    Achievement rate of LDL-C treatment goals in accordance with NCEP ATP III criteria at 4 and 8 weeks after administration of clinical trial medications, experimental, active comparator2 (Group1 : \< 160mg/dL, Group 2: \< 130mg/dL, Group 3: \< 100mg/dL)

    Time frame: week4, week8

  7. Percentage of lipid indicators change

    Percentage of lipid indicators(TC, HDL-C, TG, LDL-C/HDL-C, TC/HDL-C, non-HDL-C, Apo B) change at week 4, 8 compare to baseline, experimental, active comparator2

    Time frame: baseline, week4. week8

  8. Lipid indicators chage

    Lipid indicators(TC, HDL-C, TG, LDL-C/HDL-C, TC/HDL-C, non-HDL-C, Apo B) change at week 4, 8 compare to baseline, experimental, active comparator2

    Time frame: basline, week4, week8

07

Study locations

1 of 1 sites recruiting
  • Daegu Catholic Univ Medical Center
    Daegu, Korea, Republic of
    Recruiting
    • Ki Sik Kim, PI · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for May 2022, 22 months after the start.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 22 months is above that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2020
First posted
Dec 9, 2020
StartActual
Jul 15, 2020
Primary completionEst.
May 19, 2022
CompletionEst.
May 19, 2022
Last update
Dec 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04659070
Responsible party
Sponsor
First posted
Dec 9, 2020
Start date
Jul 15, 2020
Primary completion
May 19, 2022 (estimated)
Completion
May 19, 2022 (estimated)
Last update
Dec 9, 2020

Study contacts

Kee Sik Kim, CI
Contact
kks7379@cu.ac.kr
053-650-4455
Kyoung Hee Baek, PM
Contact
khbaek@hanlim.com
82-2-3489-6160

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Rosuvastatin · Telmisartan

Start the discussion